Contents

Preface XIII
Foreword XV
List of Contributors XVII

1 Introduction 1
Holger Schütz and Peter M. Wiedemann
References 8

1 From Scientific Analysis to Risk Policy 11

2 Risk Assessment and Risk Communication for Electromagnetic Fields:
A World Health Organization Perspective 13
T. Emilie van Deventer and Kenneth R. Foster
2.1 Introduction 13
2.2 Conceptual Framework for Risk Assessment 14
2.3 EHC on EMFs 14
2.3.1 ELF Fields 16
2.3.2 Static Fields 17
2.4 Comparison Between the WHO ELF-EHC and the California Report 18
2.5 Communicating about Risks of EMFs 19
2.6 Discussion 20
Appendix 1 22
References 23

3 Characterizing Evidence and Policy Making 25
Evi Vogel and Ginevra Delfini
3.1 Introduction 25
3.2 Science-based Evidence 25
3.2.1 From Basic Research to Recommendations 26
3.2.2 Officially Appointed Expert Committees and Self-appointed Experts 28
3.2.3 Communication of Recommendations 28
3.3 Society-based Evidence 29
3.4 Policy Making 30
3.4.1 Role of Policy Drafters in Policy Making 30
3.4.2 Role of Politicians in Policy Making 30
3.4.3 Policy Making and the Media 31
3.4.4 Policies 31
3.5 Conclusions 33
References 34

II Making Sense of Conflicting Data: Evidence Characterization in Different Research Areas 35

4 Basic Principles and Evidence Characterization of the Data from Genetox Investigations 37
Günter Obe and Vijayalaxmi
4.1 Introduction 37
4.2 Cell Cycle 37
4.3 Test Systems 38
4.3.1 COMET Assay to Evaluate Primary DNA Damage 38
4.3.2 Chromosomal Aberrations 39
4.3.3 Micronuclei 41
4.3.4 Sister Chromatid Exchanges 41
4.3.5 Other Assay Systems and Endpoints 42
4.4 Methodological Aspects 42
4.4.1 In Vitro Studies 43
4.4.1.1 CAs in HPLs 43
4.4.1.2 CAs in Fibroblasts 43
4.4.1.3 MN 43
4.4.1.4 SCEs 44
4.4.1.5 Metabolic Activation 44
4.4.2 In Vivo Studies 44
4.4.2.1 Mammals 44
4.4.2.2 Humans 44
4.5 GLP 45
4.6 Evidence Characterization and Interpretation of Genetox Results 47
4.6.1 Interpretation of Data from One Endpoint 47
4.6.2 Interpretation of Data from Four Endpoints 48
4.6.3 Interpretation of Data from Three Endpoints 48
4.6.4 Interpretation of Data from Two Endpoints 49
4.7 Genetox Studies with Electromagnetic Fields 50
References 51

5 Animal Studies 55
Alexander Lerchl
5.1 Introduction 55
5.2 Exposure Systems 57
5.3 Sham Exposure and Cage Controls 58
5.4 Replication Studies 59
5.5 Interpretation of Results 60
5.6 Conclusions 60
References 64

6 Epidemiology 67
Joachim Schüz
6.1 Introduction 67
6.2 Study Types and Risk Estimation 67
6.3 Making Sense of Conflicting Results 71
6.3.1 Temporal Relation Consistent with Cause and Effect 71
6.3.2 Strength of the Association 73
6.3.3 Dose–Response Relationship 73
6.3.4 Consistency Within and Across Studies 74
6.3.5 Specificity 74
6.3.6 Absence of Bias and Confounding 75
6.3.7 Biological Plausibility 76
6.4 Conclusions 77
References 78

7 Principles and Practice of Evidence Characterization in Environmental Clinical Case Studies 81
Caroline Herr and Thomas Eikmann
7.1 Clinical Environmental Medicine 81
7.2 Assessment of Health Complaints 81
7.2.1 Environmental Attribution 82
7.2.2 Case History 83
7.3 Exposure Assessment and Evaluation 83
7.3.1 Biomonitoring 83
7.3.2 Effect and Susceptibility Monitoring 84
7.3.3 On-site Inspection 84
7.3.4 Ambient Monitoring 84
7.4 Interdisciplinary Clinical Diagnostics 85
7.4.1 Evaluation of Clinical Cases 86
7.5 Conclusions 88
References 89
III Making Sense of Conflicting Data: Procedures for Characterizing Evidence 91

8 Characterizing Evidence with Evidence-based Medicine 93

Alexander Katalinic and Dagmar Lühmann

8.1 What is Evidence-based Medicine? 93

8.2 EbM Process 94

8.3 Five Steps of EbM 94

8.3.1 Asking Answerable Questions 95

8.3.2 Finding the Best Available Evidence 95

8.3.3 Critical Appraisal 97

8.3.4 Acting on the Evidence 98

8.3.5 Evaluate your Performance 98

8.4 Comparing the EbM to Other Approaches of Characterizing Evidence 99

References 99

9 The IARC Monographs’ Approach to Characterizing Evidence 101

Vincent James Cogliano, Robert Alexander Baan, Kurt Straif, Yann Grosse, Marie Béatrice Secretan, and Fatiha El Ghissassi

9.1 Introduction 101

9.2 Pertinent Data for Carcinogen Identification 101

9.3 International Agency for Research on Cancer Evaluations 102

9.3.1 Evaluating Epidemiologic Studies 102

9.3.2 Evaluating Bioassays in Experimental Animals 104

9.3.3 Evaluating Mechanistic and Other Relevant Data 105

9.3.4 Overall Evaluation 105

9.4 Hazard versus Risk 107

9.5 Ensuring Impartial Evaluations 108

9.6 Characterizing Evidence in the Future 108

References 109

10 The Swiss Health Risk Approach 111

Martin Röösli

10.1 Background 111

10.2 Aims 112

10.3 Approach 112

10.3.1 Evidence Rating 112

10.3.2 Relevance to Health 113

10.3.3 Exposure Levels 113

10.3.4 Summary Scheme 113

10.4 Discussion 116

10.4.1 Gradual Rating of the Evidence 116

10.4.2 Source-specific Evaluation 116

10.4.3 Lack of Data 117

10.4.4 Publication Bias 117
10.4.5 Rating of the Study Quality 118
10.4.6 Meta-analyses 118
10.5 Conclusions 119
References 119

11 Procedures for Characterizing Evidence: German Commission on Radiation Protection (Strahlenschutzkommission) 121
Norbert Leitgeb
11.1 Introduction 121
11.2 Assessment of Scientific Evidence 122
11.3 Relevance to Human Health 123
11.4 Weight of Evidence 124
11.5 Multidisciplinary Assessment 125
11.6 Regulations 126
11.7 Precautions 126
11.8 Electromagnetic Interference 128
11.9 Conclusions 128
References 128

12 Lessons from the California Electromagnetic Field Risk Assessment of 2002 131
Raymond Richard Neutra
12.1 Introduction 131
12.2 Policy Questions and Questions about Causal Claims and Arguments 131
12.3 Bradford Hill’s and Koch’s Questions 132
12.4 The Asymmetry of Some “Rule In” Tests 138
12.5 Toulmin’s Argument Anatomy and Bayes’ Theorem as a Universal Warrant 139
12.6 Special Importance of Coherence 142
12.7 Plausibility, Experimentation and Analogy 143
12.8 Causal Arguments Can Become More Transparent but Will Always Involve Judgment 147
References 149

13 Evidence Maps – A Tool for Summarizing and Communicating Evidence in Risk Assessment 151
Holger Schütz, Peter M. Wiedemann, and Albena Spangenberg
13.1 Introduction 151
13.2 Evidence Maps Approach 151
13.2.1 Background 151
13.2.2 Structure of Evidence Maps 153
13.2.3 Constructing an Evidence Map: Cancer Epidemiology 154
13.3 Insights from the Process of Building Evidence Maps 158
13.4 Conclusions 159
References 159
IV Psychological and Ethical Aspects in Dealing with Conflicting Data and Uncertainty 161

14 Perception of Uncertainty and Communication about unclear Risks 163
Peter Wiedemann, Holger Schütz, and Andrea Thalmann

14.1 Introduction 163
14.2 Uncertainty in Risk Assessment 164
14.3 Uncertainty Communication and Lay Persons’ Perception of Uncertainty Information 166
14.3.1 Intuitive Toxicology: How do Nonexperts Understand the Risk Assessment Framework? 166
14.3.2 How do People Understand Information about Relative Risks 168
14.3.3 Information about Uncertainty in Risk Assessment: How do Nonexperts Cope With It? 169
14.3.4 Uncertainty Descriptions: How do People Understand Qualitative, Quantitative and Visual Expression? 171
14.3.5 Contextual Effects 174
14.4 Lay Peoples’ Perception of Precautionary Measures 176
14.5 Outlook and Conclusions 178
References 179

15 Ethical Guidance for Dealing with Unclear Risk 185
Armin Grunwald

15.1 Ethical Guidance in Cases of Unclear Risk – The Challenge 185
15.2 Entry Points of Ethical Reflection in Situations of Unclear Risk 186
15.2.1 Entry Points of Ethical Reflection in General 186
15.2.2 Unclear Risk: Nonstandard Situations with Respect to Risk 187
15.2.3 Moral Conflicts in Situations of Unclear Risk 189
15.3 Ethical Approaches to (Unclear) Risk 191
15.3.1 Consequentialist Approach 191
15.3.2 Principle of Pragmatic Consistency 192
15.3.3 “Imperative of Responsibility” (Jonas) 193
15.3.4 Projected Time 194
15.3.5 Deontological Advice 195
15.3.6 Interim Conclusions (1) 196
15.4 Operative Approaches 197
15.4.1 Precautionary Principle 197
15.4.2 Principle of Prudent Avoidance 198
15.4.3 Interim Conclusions (2) 199
15.5 Conclusions 200
References 201
V  Practical Implications  203

16  Lessons Learned: Recommendations for Communicating Conflicting Evidence for Risk Characterization  205
Peter Wiedemann, Franziska Börner, and Holger Schütz

16.1  Introduction  205
16.2  Guiding Principles in Risk Communication  207
16.2.1  Prudence  207
16.2.1.1  Assess the Underlying Problem  207
16.2.1.2  Both Content and Process do Matter  207
16.2.2  Transparency  208
16.2.2.1  Make Your Expertise Transparent  208
16.2.2.2  Describe the Context of Your Work and the Process of Arriving at the Conclusion  208
16.2.2.3  Reveal your Evaluation Framework  208
16.2.2.4  Describe the Rules that You Use for Evaluating the Weight of Evidence  209
16.2.3  Impartiality  209
16.2.3.1  Give the Pros and Cons of Your Assessment  209
16.2.3.2  Depict the Remaining Uncertainties but Do Not Forget to Point Out the Evidence Already Available  209
16.2.4  Reasonableness  210
16.2.4.1  Explain the Process of Evaluating Evidence  210
16.2.4.2  Explain the Relevance of the Endpoints for Evaluating Human Health Risks  210
16.2.4.3  Put the Available Evidence in Perspective  210
16.2.4.4  Support Accessibility of Critical Information  211
16.2.4.5  Assess the Potential Risk  211
16.2.4.6  Put the Potential Risk in Perspective  211
16.2.5  Clarity  211
16.2.5.1  Give No More Information than Necessary  211
16.2.5.2  Be Aware of Your Language  211
16.2.5.3  Test the Perceptions of your Communication Formats  212
16.2.6  Responsibility  212
16.2.6.1  How Much Evidence is Evidence Enough for Taking Action?  212

References  213

Index  215